Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $3.267 million which missed the analyst consensus estimate of $7.438 million by 56.08 percent. This is a 45.11 percent decrease over sales of $5.952 million the same period last year.